Monopar Therapeutics

MNPR

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001645469

SEC filings (opens in a new tab)

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 7 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 10, 2026: $481.8M
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $4.53M in total: 7
13F holdersQ2 2026, +15 vs. previous quarter: 95
13F valueReported value at the end of Q2 2026: $576.1M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $0; No comparable prior period
Net income, FY2025: -$13.7M; No comparable prior period
Free cash flow, FY2025: –; No comparable prior period
Revenue, Q2 FY2026: $0; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 1.10M; Shares sold short
Change: −25.1K; −2.2% vs. previous
Days to cover: 8.80; At average daily volume

Superinvestors holding MNPR, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding MNPR at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Monopar Therapeutics insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 4, 2026 (view filing)8:15 PM ET	Nov 2	2 days	Anderson RaymondDirector	SSale	−3.14K	$68.35	−$214.7K	−36.9%5.37K after	4 lots10b5-1
Nov 4, 2026 (view filing)8:15 PM ET	Nov 2-4	2 days	Tsuchimoto Kim RDirector	SSale	−4.09K	$70.92	−$290.1K	−100.0%0 after	4 lots10b5-1
Oct 5, 2026 (view filing)5:43 PM ET	Oct 1	4 days	Starr Christopher MDirector	SSale	−8.40K	$78.50	−$659.4K	−61.9%5.17K after	3 lots10b5-1
Sep 28, 2026 (view filing)8:47 PM ET	Sep 24	4 days	Robinson ChandlerChief Executive Officer	SSale	−29.1K	$88.00	−$2.56M	−22.6%99.3K after	4 lots10b5-1
Aug 28, 2026 (view filing)8:18 PM ET	Aug 26	2 days	Tsuchimoto Kim RDirector	SSale	−4.09K	$111.39	−$455.6K	−100.0%0 after	Amended6 lots10b5-1
Aug 28, 2026 (view filing)7:41 PM ET	Aug 25	3 days	Anderson RaymondDirector	SSale	−3.14K	$111.98	−$351.8K	−36.9%5.37K after	Amended3 lots10b5-1
Aug 27, 2026 (view filing)7:29 PM ET	Aug 26	1 day	Rioux PatriceOther: Acting Chief Medical Officer	SSale	−1	$111.26	−$111.26	0.0%5.07K after	10b5-1
Dec 29, 2025 (view filing)	Dec 26	3 days	Vu Quan AnhChief Financial Officer	PPurchase	+1.50K	$69.95	+$104.9K	New position1.50K after
Dec 19, 2025 (view filing)	Dec 18	1 day	Klausner Arthur JDirector	SSale	−5.12K	$67.15	−$343.9K	−36.9%8.76K after	2 lots
Sep 26, 2025 (view filing)3:53 PM ET	Sep 24	2 days	Robinson Chandler and 4 othersChief Executive Officer	SSale	−550.2K	$63.61	−$35.0M	−66.9%272.0K after

Top 10 13F holders, Q2 2026

See all 95 holders

The largest institutional positions in Monopar Therapeutics at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding MNPR in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Jupiter Topco LLC	1,312,129	$121.7M	0.05%	+1,312,129	New
Ra Capital Management, L.P.	667,207	$61.8M	0.54%	00.0%	Unchanged
BlackRock, Inc.	348,819	$32.3M	0.00%	+32,252+10.2%	Added
Deerfield Management Company, L.P. (Series C)	323,745	$30.0M	0.31%	00.0%	Unchanged
Saturn V Capital Management LLC	311,976	$28.9M	4.14%	−33,650−9.7%	Reduced
Siren, L.L.C.	270,118	$25.0M	0.51%	00.0%	Unchanged
ADAR1 Capital Management, LLC	217,595	$20.1M	0.95%	−46,683−17.7%	Reduced
Polar Capital Holdings Plc	214,469	$19.9M	0.06%	−12,057−5.3%	Reduced
Vanguard Capital Management LLC	209,711	$19.4M	0.00%	−8,752−4.0%	Reduced
Adage Capital Partners GP, L.L.C.	209,195	$19.4M	0.03%	−100,000−32.3%	Reduced

Holders of 5% or more of MNPR

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Monopar Therapeutics.

Largest holders of MNPR from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Janus Henderson Group PLC	13G/A	19.50%1.29M shares	+0.30 ppfrom 19.20%	Nov 6, 20245 filings	Nov 14, 2025	SEC
Ra Capital Management, L.P.	13G/A	9.90%667.6K shares	0.00 ppfrom 9.90%	Oct 31, 20244 filings	Feb 17, 2026	SEC
AstraZeneca PLC	13G/A	7.80%522.7K shares	–	Oct 28, 20242 filings	Feb 6, 2026	SEC
BlackRock, Inc.	13G	5.03%338.1K shares	New	Oct 27, 20261 filing	Oct 27, 2026	SEC